FDA approved Moderna’s mRNA influenza vaccine for older adults, positioning the shot as the first licensed flu vaccine using messenger RNA technology. The decision followed a contentious period in which FDA biologics leadership initially refused to file and then later reversed the position after Moderna’s disclosure and pushback. The approval extends the first-to-market mRNA playbook beyond Covid-era products and adds a new commercial pathway for Moderna even as investors increasingly ask about the durability of its broader pipeline strategy. The regulatory sequence also highlighted ongoing scrutiny of the data package readiness for next-generation vaccine platforms. For biotech stakeholders, the episode matters less for the flu indication itself and more for what it signals about FDA’s willingness to clear mRNA vaccines under a tight review lens once information gaps are addressed.